logo

For the Inventor, By the Inventor

Bedford, MA, United States of America

Vivek Kannoth Vishnudas

This inventor holds 14 USPTO granted patents and 16 published patent applications. Top assignee: Berg LLC. Active years: 2017-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vivek Kannoth Vishnudas. Retrieved from https://idiyas.com/inventor/vivek-kannoth-vishnudas

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 

% Patents Active = 85.7

Average Co-Inventor Count = 3.9

ph-index = 3

Forward Citations = 17(Granted Patents)


Location History:

  • Newton, MA (US) (2017)
  • Bedford, MA (US) (2017 - 2023)

Company Filing History:

goldMedal14 out of 37 
 
Berg LLC
 patents

Years Active: 2017-2023

Loading Chart...
14 patents (USPTO):Explore Patents
1. 11694765 - Interrogatory cell-based assays for identifying drug-induced toxicity markers (2023-07-04),
2. 11456054 - Interrogatory cell-based assays and uses thereof (2022-09-27),
3. 11224641 - Enolase 1 (ENO1) compositions and uses thereof (2022-01-18),
4. 11091447 - UBE2K modulators and methods for their use (2021-08-17),
5. 11001891 - Methods for treating Parkinson's disease (2021-05-11),
6. 10539566 - Use of markers including filamin A in the diagnosis and treatment of prostate cancer (2020-01-21),
7. 10352947 - Use of markers in the identification of cardiotoxic agents and in the diagnosis and monitoring of cardiomyopathy and cardiovascular disease (2019-07-16),
8. 10188708 - Enolase 1 (Eno1) compositions and uses thereof (2019-01-29),
9. 10188707 - Enolase 1 (Eno1) compositions and uses thereof (2019-01-29),
10. 10061887 - Interrogatory cell-based assays and uses thereof (2018-08-28),
11. 10023864 - Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta (2018-07-17),
12. 9886545 - Interrogatory cell-based assays and uses thereof (2018-02-06),
13. 9797905 - Use of markers in the diagnosis and treatment of prostate cancer (2017-10-24),
14. 9533002 - Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β (2017-01-03),

Title: Inventor Vivek Kannoth Vishnudas: Pioneering Drug Toxicity Research

Introduction

Vivek Kannoth Vishnudas is a notable inventor based in Bedford, MA, USA, recognized for his significant contributions to the field of drug toxicity research. With a total of 14 patents to his name, Vishnudas has developed innovative solutions aimed at understanding and mitigating drug-induced toxicity.

Latest Patents

Among his most recent patents are two groundbreaking technologies designed to enhance the evaluation of drug safety. The first patent, titled "Interrogatory cell-based assays for identifying drug-induced toxicity markers," presents a novel platform technology that enables researchers to model and assess drug-induced toxicity conditions like cardiotoxicity. The second patent, "Interrogatory cell-based assays and uses thereof," focuses on analyzing biological systems to investigate disease conditions such as cancer, utilizing model building to create relevant biological insights.

Career Highlights

Vivek Kannoth Vishnudas currently works at Berg LLC, a company renowned for its transformative research in biotechnology. His career is marked by a commitment to advancing the scientific understanding of drug interactions and safety, evidenced by his substantial portfolio of patents.

Collaborations

In his innovative journey, Vishnudas collaborates with esteemed colleagues like Rangaprasad Sarangarajan and Niven Rajin Narain. These collaborations underscore the importance of teamwork in the pursuit of scientific advancements and reflect the dynamic nature of research in the biotechnology field.

Conclusion

Vivek Kannoth Vishnudas continues to make significant strides in the realm of drug toxicity research. His patents not only reflect his ingenuity as an inventor but also contribute meaningfully to the safety and efficacy of therapeutic drugs, ultimately benefiting the greater good of public health.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…